Endocyte, Inc. (NASDAQ:ECYT) announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $21.00 per share. Endocyte, Inc. (NASDAQ:ECYT) shares after opening at $24.90 moved to $25.00 on last trade day and at the end of the day closed at $23.07. Company price to sales ratio in past twelve months was calculated as 12.85 and price to cash ratio as 5.60. Endocyte, Inc. (NASDAQ:ECYT) showed a positive weekly performance of 57.58%.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) on Mar. 24 provided an overview of its three clinical development programs and financial results for the year ended December 31, 2013. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) shares advanced 1.77% in last trading session and ended the day on $1.15. RNN return on equity ratio is recorded as -81.70% and its return on assets is -49.00%. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) yearly performance is 270.97%.
Shares of MannKind (NASDAQ:MNKD) were the recipient of some unusual options trading activity on Monday. Traders purchased 21,101 call options on the company, AnalystRatings.NET reports. This is an increase of approximately 105% compared to the average daily volume of 10,311 call options. MannKind Corporation (NASDAQ:MNKD) shares moved down -3.35% in last trading session and was closed at $5.20, while trading in range of $4.87 – $5.44. MannKind Corporation (NASDAQ:MNKD) year to date (YTD) performance is 0.00%.
Arrowhead Research Corp (NASDAQ:ARWR) Begins on March 24 Dosing in Phase 2a Trial of RNAi Therapeutic ARC-520 in Chronic Hepatitis B Patients. Arrowhead Research Corp (NASDAQ:ARWR) weekly performance is -31.42%. On last trading day company shares ended up $16.33. Arrowhead Research Corp (NASDAQ:ARWR) distance from 50-day simple moving average (SMA50) is -12.77%. Analysts mean target price for the company is $28.75.